OXURION NV TBGNF overview

Leuven, BELGIUM – September 3, 2024 – 09:30 PM CET - Oxurion NV (Euronext Brussels: OXUR) , a biopharmaceutical company headquartered in Leuven, announces the opening of a private judicial reorganization procedure (GRP), approved by the Leuven court on August 22, 2024. On November 20, 2023, the company announced that the results of its KALAHARI Phase 2, Part B study were unsatisfactory and that it had decided to prepare for bankruptcy filing. However, on December 28, 2023, the company...

Leuven, BELGIUM – September 3, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on August 30, 2024, from Atlas Special Opportunities, LLC indicating that as of July 22, 2024, it held 2,028,567,725 shares of the then outstanding 13,362,647,372 shares, and...

Leuven, BELGIUM – September 3, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today confirms that the last day of trading of its current shares on Euronext Brussels was September 2, 2024. This date marks a key step in the context of the consolidation of the Company's shares, which will take place on September 3, 2024. Details of the Consolidation of Shares The Consolidation of the Company's shares will be carried out based on...